NO CLINICALLY SIGNIFICANT PHARMACOKINETIC INTERACTION BETWEEN SOVAPREVIR AND ACH-3102 IN HEALTHY VOLUNTEERS

dominant species in all but one subject.The one exceptional subject carried the L31M substitution at baseline; the dominant species transitioned first to the L31M variant and later to a M28T/Q30H double substitution, indicating inhibition of the L31M variant by ACH-3102 at the doses examined.Conclusions: Despite the presence at baseline of variants resistant to first generation NS5A inhibitors, robust antiviral activity was seen in all GT-1a hepatitis C patients administered ACH-3102 in the clinical proof-of concept study.These data are consistent with the previously reported in vitro potencies of ACH-3102 against wildtype GT-1a HCV and against the majority of variants with mutations associated with viral resistance to first generation NS5A inhibitors, warranting the clinical investigation of ACH-3102 as a component of all-oral regimens for the treatment of chronic hepatitis C.